Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original human data
PubMed 42437212 · doi:10.7759/cureus.110657
What was done
This narrative review examined the landscape of unregulated peptide use within online biohacking and wellness communities. The authors analyzed the intersection of digital promotion, gray-market distribution, consumer practices (such as self-injection, stacking, and informal titration), product-quality uncertainties, regulatory ambiguity, and pharmacovigilance gaps.
What was found
The abstract reports no numerical data or quantitative outcomes. Qualitatively, it highlights how online platforms normalize consumer experimentation with non-prescribed, poorly traceable peptide products possessing uncertain identity, purity, potency, sterility, and safety profiles.
Why it matters
The paper outlines how growing gray-market peptide self-administration complicates clinical practice, emphasizing the need for clinician awareness, adverse-event reporting, and regulatory clarity to separate legitimate therapeutics from hazardous consumer use.
Limits
This is a narrative review lacking systematic search methods, empirical data, or quantitative metrics. The abstract does not measure prevalence, specific adverse-event rates, or the clinical outcomes of unregulated peptide consumption.
Cited by
- context Analytical testing of gray-market research peptides imported from China has identified batches containing contaminants, heavy metals, and endotoxins.